Abstract:BACKGROUND:Prostate cancer is one of the most commonly diagnosed cancers and one of the most common causes of cancer-related deaths among men worldwide. Patients who are diagnosed with localized prostate cancer and treated with radical prostatectomy often respond well to therapy. The current standard therapy for prostate cancer involves maximal surgical resection, followed by radiotherapy and chemotherapy. Clarifying the molecular mechanism of tumor proliferation and recurrence becomes more and more important for clinical therapies of prostate cancer.METHODS:Quantitative Real-Time PCR and Western-blot were used in the detection of mRNA and protein expression. Lentivirus infection was used to overexpress or knockdown the target gene. Flow cytometry analysis was performed to test protein expression and apoptosis level. Immunohistochemistry was used to identify protein expression in tissue. Statistical differences between the two groups are evaluated by two-tailed t-tests. The comparison among multiple groups is performed by one-way Analysis of Variance (ANOVA) followed by Dunnett's posttest. The statistical significance of the Kaplan-Meier survival plot is determined by log-rank analysis.RESULTS:In this study, we identified that FOXM1 expression was significantly enriched in prostate cancer compared with normal tissue. Additionally, FOXM1 was functionally required for tumor proliferation and its expression was associated with poor prognosis in prostate cancer patients. Mechanically, FOXM1-dependent regulation of EZH2 is essential for proliferation and progression in prostate cancer.CONCLUSION:Taken together, our data suggest that oncogenic transcription factor FoxM1 is up-regulated in prostate cancer, suggesting that the growth of cancer cells may depend on FOXM1 activity. FOXM1 may serve as a clinical prognostic factor and a therapeutic target for prostate cancer.

FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.

[Foxo3a Signaling Pathway in Prostate Cancer: Progress in Studies].

SIRT3 Inhibits Prostate Cancer Metastasis Through Regulation of FOXO3A by Suppressing Wnt/β-catenin Pathway.

Regulation of FOXO3a/β-catenin/GSK-3β Signaling by 3,3′-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Prostate Cancer Cells.

MiR-142-3p Functions As an Oncogene in Prostate Cancer by Targeting FOXO1

FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L.

FOXO3a inhibits the EMT and metastasis of breast cancer by regulating TWIST-1 mediated miR-10b/CADM2 axis

FOXO3a-ROS Pathway is Involved in Androgen-Induced Proliferation of Prostate Cancer Cell

FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression

FOXD3, Frequently Methylated in Colorectal Cancer, Acts As a Tumor Suppressor and Induces Tumor Cell Apoptosis under ER Stress Via P53.

Loss of FOXN3 in Colon Cancer Activates Beta-Catenin/tcf Signaling and Promotes the Growth and Migration of Cancer Cells.

CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer

Inhibition of FOXQ1 Induces Apoptosis and Suppresses Proliferation in Prostate Cancer Cells by Controlling BCL11A/MDM2 Expression.

FOXO3a Negatively Regulates Mir-155-5p Expression to Impact the Proliferation and Invasion of Renal Cell Carcinoma

Critical Role of FOXO3a in Carcinogenesis

FOXO3 Programs Tumor-Associated DCs to Become Tolerogenic in Human and Murine Prostate Cancer.

FOXO4 Inhibits the Migration and Metastasis of Colorectal Cancer by Regulating the APC2/β-Catenin Axis

FOXD3 Suppresses Epithelial–mesenchymal Transition Through Direct Transcriptional Promotion of SMAD7 in Esophageal Squamous Cell Carcinoma

Circular RNA Circfoxo3 Promotes Prostate Cancer Progression Through Sponging Mir-29A-3p.

FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer.

FOXO3a-interacting proteins' involvement in cancer: a review